The Expression Of β-catenin In Endometrioid Adenocarcinoma Progesterone Resistance Cells And Tissues

Purpose: Endometrial cancer(EC) is one of the most common gynecological malignancies worldwide. The most common histological type of EC is endometrioid adenocarcinoma, which comprises approximately 85 % of all EC cases. Surgery is the first choice for patients with endometrial adenocarcinoma. Progestogen therapy is an important for the young who perserve reproductive function and the late recurrence patients, of endometrial carcinoma. However, about 40%~50% patients are not sensitive to progestogen therapy and have poor prognosis. In order to further enhance progesterone effectiveness of endometrioid adenocarcinoma, β-catenin ecpression was detected in progesterone resistance cells and tissues.Methods:β-catenin expression was detected in Ishikawa cells and medroxyprogesterone acetate resistant cells(Ishikawa-MPA) by realtime PCR; and immunohistochemical and realtime PCR were used to detect β-catenin expression in clinical specimens who suffered fertility-sparing treatments by progesterone were obtained between January 2012 and June 2015 from 20 atypical hyperplasia and Ia1 stage at the Department of Obstetrics and Gynecology, the first hospital of lanzhou university.Results:β-catenin expression was higher in Ishikawa-MPA cells comapared to Ishikawa cells(P = 0.007, **P < 0.01). Also, mRNA and protein expression level of β-catenin were both higher in progesterone resistance tissues higher than sensitive tissues(mRNA level: P = 0.000, ***P < 0.001; protein levels: P = 0.003, **P < 0.01).Conclusion: Progesterone resistance is closely related to Wnt/β-catenin signaling pathway and Wnt/β-catenin signaling pathway inhibitors may help resistance reversal during progesterone therapy.